Feb 18 (Reuters) - Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who accused the company of conspiring with industry rivals ...

ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal ...

Analysts have suggested its financial troubles could make a sale more difficult, as could untangling Sandoz from Novartis' broader manufacturing operations, although the launch of new biosimilars ...

53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in USStrengthens US immunology ...

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind it. The agreement – which ...

Sandoz Group said it would pay $275 million to settle claims from some plaintiffs in a generics drug pricing antitrust lawsuit in the U.S. The Swiss generics-medicine company said Tuesday that it ...

Richard Saynor, CEO of Sandoz, said: “We delivered strong results in our first full year as an independent company. At the same time, we made excellent progress in transforming the business ...

Most generics and biosimilars in the US contain ingredients made elsewhere or are produced entirely abroad, which will hit consumers immediately, Richard Saynor, the chief executive officer of Sandoz ...